The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The company also reported significant progress toward its internally defined Sustainable Development Goals
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The expansion includes a larger technical and service team and increased local procurement
This recognition demonstrate excellence in intellectual property (IP) value creation.
The move strengthens GBL’s clinical-stage presence in the United States
India plays a critical role in Bristol Myers Squibb’s global strategy
Subscribe To Our Newsletter & Stay Updated
